Citation Tools
Lupus
Original research
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years